Denali Therapeutics (DNLI)
(Delayed Data from NSDQ)
$15.43 USD
+0.47 (3.14%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $15.42 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Denali Therapeutics Inc. (DNLI) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$40.60 | $95.00 | $24.00 | 171.39% |
Price Target
Based on short-term price targets offered by 15 analysts, the average price target for Denali Therapeutics Inc. comes to $40.60. The forecasts range from a low of $24.00 to a high of $95.00. The average price target represents an increase of 171.39% from the last closing price of $14.96.
Analyst Price Targets (15)
Broker Rating
Denali Therapeutics Inc. currently has an average brokerage recommendation (ABR) of 1.24 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 17 brokerage firms. The current ABR compares to an ABR of 1.25 a month ago based on 16 recommendations.
Of the 17 recommendations deriving the current ABR, 15 are Strong Buy, representing 88.24% of all recommendations. A month ago, Strong Buy represented 87.5%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 15 | 15 | 14 | 14 | 14 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.24 | 1.24 | 1.25 | 1.25 | 1.25 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
2/28/2024 | Wedbush Securities | Laura Chico | Strong Buy | Strong Buy |
2/27/2024 | BTIG | Thomas Shrader | Strong Buy | Strong Buy |
2/22/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
11/9/2023 | Not Identified | Not Identified | Hold | Hold |
11/7/2023 | SVB Securities | Marc Goodman | Strong Buy | Strong Buy |
10/25/2023 | Cantor Fitzgerald & Co | Josh Schimmer | Strong Buy | Strong Buy |
9/6/2023 | B. Riley Securities | Mayank Mamtani | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.24 |
ABR (Last week) | 1.24 |
# of Recs in ABR | 17 |
Average Target Price | $40.60 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 76 of 252 |
Current Quarter EPS Est: | -0.67 |